Eileen Liao

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky et al. · The Lancet Oncology · 2014 · 260 citations

Hematological Malignancy, Medicine, Hematology +10

Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With <i>RPGR</i> Gene Variations

Lenore von Krusenstiern, Jiajun Liu, Eileen Liao et al. · JAMA Ophthalmology · 2023 · 56 citations · Full text

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky et al. · Leukemia · 2019 · 48 citations · Full text

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

Paul G. Richardson, Craig C. Hofmeister, Cara A. Rosenbaum et al. · British Journal of Haematology · 2018 · 34 citations · Full text

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G. Richardson, Craig C. Hofmeister, Cara A. Rosenbaum et al. · Blood · 2013 · 31 citations